Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.49 |
| ▸ | HTR2B | P41595 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | HTR6 | P50406 | 5/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3804499 | 0.99 | HTR2C (0.48) | HTR2CHTR2BHTR2AHTR6HTR1D | |
| SCHEMBL1163198 | 0.91 | HTR2C (0.47) | HTR2CHTR2BHTR2AHTR6HTR1D | |
| SCHEMBL12558410 | 0.87 | HTR2A (0.46) | HTR2CHTR2AHTR1DTRPM8KDM1A | |
| SCHEMBL12558406 | 0.87 | KDM1A (0.40) | HTR2ABCHEKDM1A | |
| SCHEMBL3809146 | 0.87 | HTR6 (0.46) | HTR2CHTR2BHTR2AHTR6HTR1D | |
| SCHEMBL3804929 | 0.86 | HTR2A (0.51) | HTR2CHTR2BHTR2AHTR6HTR1D | |
| SCHEMBL13592843 | 0.85 | HTR2C (0.50) | HTR2CHTR2BHTR2AHTR6HTR1D | |
| Hydrochloric Acid SCHEMBL4391300 | 0.84 | HTR2C (0.49) | HTR2CHTR2BHTR2AHTR6HTR1D | |
| SCHEMBL19650679 | 0.84 | TAAR1 (0.40) | HTR2CTAAR1BCHEKDM1A | |
| SCHEMBL4397110 | 0.83 | HTR2A (0.42) | HTR2CHTR2BHTR2AHTR6HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-24 | — | — | US | disclosed |
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR2C 27/4885HTR2B 31/4885HTR2A 34/4885 |
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | HTR2C 30/4885HTR2B 32/4885HTR2A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.